Achieve commercial success: the value of a sound manufacturing strategy

Output from a CGTC led panel discussion at the ISCT 2022 Commercialization Signature Series

Earlier this year, we attended the 4th Annual International Society for Cell & Gene Therapy (ISCT) Commercialization Signature Series event, which brought together ISCT members and invited advisors and prominent opinion leaders from across the cell and gene therapy value chain.

We were invited to the event to lead an informative panel session on “How to realise the strategic value of manufacturing in driving commercial success”.

The panel focused on the challenges of manufacturing cell and gene therapy products, and discussed working with contract development and manufacturing companies (CDMOs) and the increasing importance of understanding chemistry, and manufacturing.

The key outcomes from the session, including “what you should look out for when working with a CDMO” have been summarised in a write up of the day published on Cell and Gene Therapy Insights.